Raven Industries, Inc. (RAVN Quick QuoteRAVN ) announced an update on its deal with CNH Industrial N.V. (CNHI Quick QuoteCNHI ) , signed in June 2021. The transaction was green lighted by the company’s shareholders at a special meeting held yesterday.
In the last trading session, shares of Raven dipped 0.24%, closing at $57.60.
Raven is based in Sioux Falls, SD and is one of the leading companies engaged in providing precision agriculture technology. It has three divisions, namely Aerostar, Engineered Films and Applied Technology. Its revenues totaled $348.4 million in the 12 months ended Jan 31, 2021.
Inside the Headlines
The deal was approved by 99% of the nearly 71% of Raven’s stakeholders that voted at the special meeting. The completion of the transaction is expected in the fourth quarter of 2021 after receiving necessary approvals from the Defense Counterintelligence and Security Agency (DCSA) and the Committee on Foreign Investment in the United States (CFIUS).
A brief discussion on the signed agreement is provided below:
The deal inked between the parties calls for the buyout of Raven by CNH Industrial. The transaction was valued at $58 per share or $2.1 billion enterprise value and will be funded by CNH Industrial with available cash.
The transaction is expected to enhance Raven’s capabilities in the agriculture technology space and boost its shareholder value. CNH Industrial plans to take a strategic review of Aerostar and Engineered Films divisions after the transaction is over. While Aerostar is a leader in the stratospheric platform industry, Engineered Films is well-known in the performance specialty films industry. The review will help boost the capabilities of both divisions and enhance shareholder value.
By calendar year 2025, the Raven-CNH Industrial transaction is anticipated to generate revenues (run-rate) worth $400 million. Incremental earnings before interest, tax, depreciation and amortization are expected to be $150 million.
Top 5 Value Stocks To Invest In Right Now: Mesoblast Limited(MESO)
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
- [By Stephan Byrd]
Synopsys, Inc. (NASDAQ:SNPS) – Equities researchers at DA Davidson raised their Q3 2020 earnings per share estimates for shares of Synopsys in a research report issued on Wednesday, April 3rd. DA Davidson analyst T. Diffely now forecasts that the semiconductor company will post earnings of $0.89 per share for the quarter, up from their prior estimate of $0.86. DA Davidson currently has a “Buy” rating and a $135.00 price target on the stock. DA Davidson also issued estimates for Synopsys’ Q4 2020 earnings at $0.92 EPS.
- [By Lee Jackson]
This semiconductor design stock is another Wall Street favorite and the top pick for 2018 at RBC. Synopsys Inc. (NASDAQ: SNPS) is the largest provider of electronic design automation (EDA) software used to design, verify and layout semiconductor chips and electrical systems.
Top 5 Value Stocks To Invest In Right Now: Kayne Anderson Energy Development Company(KED)
Kayne Anderson Energy Development Company is a close-ended balanced mutual fund launched and managed by KA Fund Advisors, LLC. The fund is co-managed by Kayne Anderson Capital Advisors, L.P. It invests in public equity and fixed income markets of the United States. The fund also invests in private equity markets. It primarily invests in privately-held energy-related master limited partnerships, publicly-traded MLPs, and other energy companies. Kayne Anderson Energy Development Company was formed on May 24, 2006 and is domiciled in United States.